We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
An in-depth look at Zykadia (ceritinib) for ALK-positive metastatic NSCLC, covering its uses, common and serious side effects, precautions, and management strategies for Indian patients.

Zykadia, with the active ingredient ceritinib, is a prescription medication approved for adults diagnosed with a specific type of non-small cell lung cancer (NSCLC). This type is known as anaplastic lymphoma kinase-positive (ALK+) and metastatic (meaning it has spread to other parts of the body). If you or a loved one has been diagnosed with ALK-positive metastatic NSCLC, your doctor might discuss Zykadia as a potential treatment option. This blog post aims to provide a comprehensive overview of Zykadia, focusing on its potential side effects, how it works, and important considerations for patients in India.
Zykadia is a type of targeted therapy. Unlike traditional chemotherapy that affects all rapidly dividing cells, targeted therapies are designed to attack specific molecules or pathways involved in cancer growth. In the case of Zykadia, it inhibits the ALK protein, which is abnormally active in ALK-positive NSCLC, thereby slowing down or stopping cancer cell growth.
While Zykadia can be an effective treatment, like all medications, it can cause side effects. Many of these are mild and manageable. It is crucial to discuss any side effects you experience with your doctor. Some of the more commonly reported mild side effects include:
Most mild side effects are temporary and can often be managed with supportive care. However, if any of these symptoms are persistent, severe, or bothersome, do not hesitate to consult your healthcare provider. It's important not to stop taking Zykadia unless specifically advised by your doctor.
Although less common, Zykadia can also cause serious side effects that require immediate medical attention. It is vital to be aware of these potential risks:
If you experience any signs of a serious side effect, contact your doctor immediately. If the symptoms feel life-threatening, call emergency services (like 108 in India) or go to the nearest hospital emergency room without delay.
Before starting Zykadia, it's essential to discuss your complete medical history with your doctor, including any pre-existing conditions such as diabetes, heart problems, liver issues, or lung diseases. Also, inform them about all medications, supplements, and herbal products you are currently taking, as interactions can occur.
Zykadia can harm a developing fetus. If you are a woman who can become pregnant, you must use effective birth control during treatment and for at least 6 months after your last dose. If you are a male with a partner who can become pregnant, you should also use birth control during treatment and for at least 3 months after your last dose.
You should not breastfeed while taking Zykadia and for at least 2 weeks after your last dose. If you are breastfeeding or planning to breastfeed, discuss the risks and benefits with your doctor.
Your doctor will likely schedule regular blood tests to monitor your liver function, blood sugar levels, heart rhythm, and other parameters to check for side effects and ensure the medication is working effectively.
Zykadia is prescribed based on a confirmed diagnosis of ALK-positive metastatic NSCLC. This diagnosis is typically made through biopsy and specific genetic testing of the tumor tissue.
You should consult your doctor immediately if you experience:
Regular follow-up appointments are crucial for managing your treatment and any potential side effects.
The management of Zykadia side effects depends on their severity and type. Your doctor may:
It is essential to work closely with your healthcare team to manage side effects effectively and continue your cancer treatment.
While Zykadia is a targeted cancer therapy and its side effects cannot be entirely prevented, certain lifestyle measures can help manage them:
Zykadia (ceritinib) is used to treat adults with a specific type of non-small cell lung cancer (NSCLC) that is ALK-positive and has spread to other parts of the body (metastatic).
Zykadia can cause high blood sugar levels (hyperglycemia), which may lead to or worsen type 2 diabetes in some individuals. Regular blood sugar monitoring is important.
Severe diarrhea should be reported to your doctor immediately. They may adjust your Zykadia dosage or prescribe medication to manage the diarrhea and prevent dehydration.
Zykadia is a targeted therapy, not traditional chemotherapy. It works by specifically targeting the ALK protein involved in cancer growth.
The duration of side effects can vary. Some mild side effects may be temporary and resolve on their own or with management. Serious side effects require immediate medical attention and their duration depends on the condition and treatment.
Zykadia is an important medication for individuals with ALK-positive metastatic NSCLC. Understanding its potential side effects, both common and serious, is crucial for patients and their caregivers. Open communication with your healthcare provider about any symptoms or concerns is key to managing treatment effectively and ensuring the best possible outcomes. Regular monitoring and adherence to medical advice are vital components of successful cancer treatment in India.
Learn about potential side effects of CML treatments like TKIs, interferon, chemotherapy, and stem cell transplants. Understand what to expect and how to communicate with your doctor for effective management.
April 1, 2026

Discover essential support resources, financial aid options, and community connections for individuals navigating life with Chronic Myeloid Leukemia (CML). Find practical advice and empathetic guidance.
April 1, 2026
Explore targeted therapy for multiple myeloma. Learn how these precision treatments work, their types, potential side effects, and how they're used alongside other therapies to manage this blood cancer.
April 1, 2026